New Study: NPS+ Asthma/COPD (US)

From: Fast Market Research, Inc.
Published: Wed Jun 08 2016

FDCs are a hit in the US Asthma/COPD market. How does your brand measure up?

In a recent brand satisfaction survey of US pulmonologists and GPs, 3 of the 4 leading asthma/COPD brands were fixed-dose combinations. Did one of them take top spot? Find out how they scored, how single agent therapies stack up, and where your brand ranks.

This report compares brand loyalty for 9 major Asthma/COPD treatments from AstraZeneca, Boehringer, GSK, Novartis, and Roche

* How likely doctors are to recommend your brand-and your competitors.
* Which marketing messages are likely to succeed.
* Your "Brand DNA": What doctors really think about your brand.

Easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear-information you can use to improve your brand's health, and boost your market share.

Full Report Details at

Reasons to Get this Report

Get Answers to Key Questions about Asthma/COPD Treatments

* Advair (fluticasone propionate/salmeterol; GSK): Advair and Symbicort have similar NPS scores. Which brand has more Promoters?
* Arcapta (indacaterol; Novartis): Is lack of experience with Arcapta preventing doctors from recommending it?
* Breo Ellipta (fluticasone furoate/vilanterol; GSK): How concerned are doctors about Breo Ellipta's cost and insurance restrictions?
* Daliresp (roflumilast; AstraZeneca): Does Daliresp earn more doctor recommendations for being effective or easy to administer?
* Nucala (mepolizumab; GSK): Nucala is recommended by Promoters of every other brand but which?
* Spiriva (tiotropium; Boehringer): Are Spiriva's Passives closer to becoming Promoters or Detractors?
* Symbicort (budesonide/formoterol; AstraZeneca): How do some Symbicort Promoters and Detractors say it compares to Advair?
* Tudorza (aclidinium; AstraZeneca): Could patients' difficulties with its unique inhaler be preventing Detractors from recommending Tudorza?
* Xolair (omalizumab; Novartis/Roche): Which brand stands to gain more share by converting Detractors into Promoters, Breo Ellipta, Tudorza, or Xolair?

Top Takeaways

* Four of the nine surveyed brands have a positive NPS: But the top three score 2-3 times as high as the nearest competitor.
* FDCs doing well: Fixed-dose combination therapies tend to outscore monotherapies overall, earning 3 of the top 4 Net Promoter Scores.
* Three brands poised for a massive share gain: if they can win over their Detractors and turn them into Promoters. One of the three is a top-4 brand.
* Doctors not afraid to try new treatments: 90-100% of nearly every brand's Promoters also recommend one newer-to-market brand.
* Moderate satisfaction, low exclusivity: over 25% of doctors surveyed are unsatisfied with available asthma/COPD drugs. Less than 15% promote one brand exclusively.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
- NPS+ Psoriasis (EU5)
- NPS+ HIV (EU5)
- NPS+ Psoriasis (US)

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »